Circadian rhythm of irinotecan tolerability in mice

Chronobiology International

Volumn 21, Issue 4-5, 2004, Pages 613-630

  Filipski, Elisabeth ^a   Lemaigre, Guy ^a   Liu, Xu Hui ^a   Méry Mignard, Dominique ^b   Mahjoubi, Mondher ^b   Lévi, Francis ^a  

^a INSERM   (France)

^b SANOFI   (France)

Author keywords

Camptothecin Irinotecan; Chronopharmacology; Circadian rhythms; CPT 11; Mice; Toxicity

Indexed keywords

IRINOTECAN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL CYCLE G2 PHASE; CIRCADIAN RHYTHM; CONTROLLED STUDY; CONVALESCENCE; DARKNESS; DNA DAMAGE; DRUG TOLERABILITY; INTESTINE INJURY; LEUKOPENIA; LIGHT; MALE; MORTALITY; MOUSE; NEUTROPENIA; NONHUMAN; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; VALIDATION PROCESS; WEIGHT REDUCTION;

AGRANULOCYTOSIS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CAMPTOTHECIN; CELL CYCLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; DNA TOPOISOMERASES, TYPE I; DRUG TOLERANCE; ENZYME INHIBITORS; INTESTINES; LEUKOPENIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PHOTOPERIOD; WEIGHT LOSS;

ANIMALIA;

EID: 4544232784     PISSN: 07420528     EISSN: None     Source Type: Journal    
DOI: 10.1081/CBI-120040183     Document Type: Article

References (42)

1. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., Hoshi, A. (1993). Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84:697-702.
2. Bjarnason, G. A., Jordan, R. (2002). Rhythms in human gastrointestinal mucosa and skin. Chronobiol. Int. 19(1): 129-140.
3. Bjarnason, G. A., Jordan, R. C. K., Sothern, R. B. (1999). Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am. J. Pathol. 154(2):613-622.
4. Boughattas, N., Lévi, F., Fournier, C., Lemaigre, G., Roulon, A., Hecquet, B., Mathé, G., Reinberg, A. (1989). Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane (trans-1) oxalatoplatinum(II) in mice. Cancer Res. 49:3362-3368.
5. Caussanel, J. P., Lévi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., Mathe, G. (1990). Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 82:1046-1050.
6. Dean, P., Jett, J. (1974). Mathematical analysis of DNA distributions derived from flow micro-fluorimetry. J. Cell Biol. 60:523-527.
7. Douillart, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., Rougier, P. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355:1041-1047.
8. Dunlap, J. C. (1999). Molecular bases for circadian clocks. Cell 96:271-290.
9. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., Taguchi, T. (1992). A phase I study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10:16-20.
10. Gandia, D., Abigerges, D., Armand, J. P., Chabot, G., Da Costa, L., De Forni, M., Mathieu-Boue, A., Herait, P. (1993). CPT-11 induced cholinergic effects in cancer patients. J. Clin. Oncol. 11:196-197.
11. Giacchetti, S. (2002). Chronotherapy of colorectal cancer. Chronobiol. Int. 19(1):207-219.
12. Giacchetti, S., Zidani, R., Goldwasser, F., Brézault-Bonnet, C., Tigaud, J. M., Mormont, C., Montembault, S., Misset, J. L., Lévi, F. (1999). Chronomodulated CPT-11. A pilot study. Proc. Am. Soc. Clin. Oncol. 18:259a(abstr. 996).
13. 2-phase arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:4430-4437.
14. Hsiang, Y. H., Liu, L. F. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-1726.
15. Hsiang, Y. H., Lihou, M. G., Liu, L. F. (1989). Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082.
16. Hsiang, Y. H., Hertzberg, R., Hecht, S., Liu, L. F. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878.
17. Ikuno, N., Soda, H., Watanabe, M., Oka, M. (1995). Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 87:1876-1883.
18. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., Sato, K. (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51:4187-4191.
19. Kirichenko, A. V., Rich, T. A. (1999). Radiation enhancement by 9-amino-camptothecin: the effect of fractionation and timing of administration. Int. J. Radiat. Oncol. Biol. Phys. 44:659-664.
20. Klein, D. C., Moore, R. Y., Reppert, S. M. (1991). Suprachiasmatic Nucleus, the Mind's Clock. Oxford: Oxford University Press, 467 pp.
21. Kume, K., Zylka, M. J., Sriram, S., Shearman, L. P., Weaver, D. R., Jin, X., Maywood, E. S., Hastings, M. H., Reppert, S. M. (1999). mCRY1 and mCRY2 are essential components of the negative limb of the arcadian clock feedback loop. Cell 98:193-205.
22. Lévi, F. (2001). Chronotherapy of cancer. Lancet Oncology 2:307-315.
23. Lévi, F. (2002). From arcadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 19(1):1-19.
24. Lévi, F., Zidani, R., Misset, J. L. (1997). For the International Organization for Cancer Chronotherapy Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686.
25. Lévi, F., Metzger, G., Massari, C., Milano, G. (2000b). Oxaliplatin. pharmaco-kinetics and chronopharmacological aspects. Clin. Pharmacokinet. 36:1-21.
26. Lévi, F., Zidani, R., Llory, J. F., Dogliotti, L., Perpoint, B., Iacobelli, S., Chollet, P., Focan, C., Garufi, C., Le Rol, A., Giacchetti, S., Misset, J. L. (2000a). For the International Organization for Cancer Chronotherapy Final Efficacy Update at 7 Years of flat vs Chronomodulated Infusion (Chrono) of Oxaliplatin, 5-Fluorouracil and Leucovorin as First Line Treatment of Metastatic Colorectal Cancer. In: Proc. 36th Ann. Meeting Am. Soc. Clin. Oncol., May 20-23, 2000, New-Orleans: U.S.A., Vol. 19, 242a (abstr. # 936).
27. Lévi, F., Zidani, R., Vannetzel, J. M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., Iacobelli, S., Adam, R., Kunstlinger, F., Gastiaburu, J., Bismuth, H., Jasmin, C., Misset, J. L. (1994). Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst. 86:1608-1617.
28. Li, X. M., Liu, X. H., Filipski, E., Metzger, G., Delagrange, P., Jeanniot, J. P., Lévi, F. (2000). Relationship of atypical melatonin rhythm with two arcadian clock outputs in B6D2F1 mice. Am. J. Physiol.-Regul. Integ. Comp. Physiol. 278:R924-R930.
29. Li, X. M., Metzger, G., Filipski, E., Boughattas, N., Lemaigre, G., Hecquet, B., Filipski, J., Lévi, F. (1997). Pharmacologic modulation of reduced glutathione (GSH) arcadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice. Toxicol. Appl. Pharmacol. 143:281-290.
30. Marchenay, C., Cellarier, E., Lévi, F., Rolhion, C., Kwiatkowski, F., Dubray, C., Claustrat, B., Madelmont, J. C., Chollet, P. (2001). Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int. J. Cancer 91:60-66.
31. Nelson, W., Liang Tong, Y., Lee, J. K., Halberg, F. (1979). Methods for cosinor-rhythmometry. Chronobiologia 6:305-323.
32. Ohdo, S., Makinosumi, T., Ishizaki, T., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N. (1997). Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther 283:1383-1388.
33. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ishimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S., Ota, K. (1990). An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1907-1912.
34. Okamura, H., Miyake, S., Sumi, Y., Yamaguchi, S., Yasui, A., Muijtjens, M., Hoeijmakers, J. H., Horst, G. T. (1999). Photic induction of mPer1 and mPer2 in cry-deficient mice lacking a biological clock. Science 286:2531-2534.
35. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P., Jacques, C. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412.
36. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., Miller, L. L. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl. J. Med. 343:905-914.
37. Schibler, U., Sassone-Corsi, P. (2002). A web of circadian pacemakers. Cell 111:919-922.
38. Shearman, L. P., Sathyanarayanan, S., Weaver, D. R., Maywood, E. S., Chaves, I., Zheng, B., Kume, K., Lee, C., van den Horst, G. T. J., Hastings, M. H., Reppert, S. M. (2000). Interacting molecular loops in the mammalian circadian clock. Science 288:1013-1018.
39. Sorbye, H., Dahl, O., Smaaland, R. (1997). The Effect of Morning or Late Evening Administration of Irinotecan (CPT-11) on Hematological Toxicity. In: Proc. Int. Cong. on Chronobiology, Septembre 7-11, 1997, Paris, France; Chronobiol. Int. 1997, 14 (suppl. 1).
40. Suzuki, A., Kato, M. (1996). Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm. Exp. Cell Res. 227:154-159.
41. Tampellini, M., Filipski, E., Liu, X. H., Lemaigre, G., Li, X. M., Vrignaud, P., François, E., Bissery, M.-C., Lévi, F. (1998). Docetaxel chronopharmacology in mice. Cancer Res. 58:3896-904.
42. Touitou, Y., Portaluppi, F., Smolensky, M. H., Rensing, L. (2004). Ethical principles and standards for the conduct of human and animal biological rhythm research. Chronobiol. Int. 21(1): 161-170.